Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)
28 December 2022 - 9:28AM
Edgar (US Regulatory)
December 27, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Delaying Amendment for Arcturus Therapeutics Holdings Inc. Registration
Statement on Form S-3 (File No. 333-269003)
Ladies and Gentlemen:
Reference is made to the Registration Statement on Form S-3 (File No.
333-269003) filed with the Securities and Exchange Commission (the “Commission”) by Arcturus Therapeutics Holdings Inc.
on December 23, 2022 (the “Registration Statement”). Pursuant to Rule 473(c) of the Securities Act of 1933,
as amended (the “Act”), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into
the facing page of the Registration Statement:
“The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities Act of 1933,
as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said section
8(a), may determine.”
No fees are required in connection with this filing. If you have
any questions or comments in connection with this delaying amendment, please call Jeffrey A. Baumel, Dentons US LLP, at (973)
912-7189 or Grant Levine, Dentons US LLP, at (212) 768-5384, outside counsel to the Company.
|
Sincerely, |
|
Arcturus Therapeutics Holdings Inc. |
|
|
|
/s/ Joseph E. Payne |
|
|
|
Joseph E. Payne |
|
Chief Executive Officer |
cc: |
Jeffrey A. Baumel, Dentons US LLP
Ilan Katz, Dentons US LLP
Grant Levine, Dentons US LLP |
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2023 to Apr 2024